Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
27 dec 2006 - 11:03
Statutaire naam
Crucell N.V.
Titel
Merck & Co., Inc. and Crucell Sign Cross-licensing Agreement on Vaccine Production Technology
Bericht
Leiden, the Netherlands, December 27, 2006 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a cross-licensing agreement with Merck & Co., Inc. In addition to previously licensed rights to PER.C6, the agreement opens the way for Merck to use Crucell technology on an exclusive basis in additional undisclosed vaccine fields. In return, Crucell receives access to Merck’s large scale manufacturing technology for its AdVac®-based vaccines
Datum laatste update: 19 december 2025